G3.5 PAMAM dendrimers enhance transepithelial transport of SN38 while minimizing gastrointestinal toxicity

Journal of Controlled Release

Volumn 150, Issue 3, 2011, Pages 318-325

  Goldberg, Deborah S ^a,b   Vijayalakshmi, Nirmalkumar ^c   Swaan, Peter W ^a,b   Ghandehari, Hamidreza ^a,c,d  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

^c UNIVERSITY OF UTAH   (United States)

^d Department of Electrical and Computer Engineering   (United States)

Author keywords

7 ethyl 10 hydroxy camptothecin; Caco 2; Oral drug delivery; PAMAM dendrimers; Transepithelial transport

Indexed keywords

10-HYDROXY-CAMPTOTHECIN; CACO-2; ORAL DRUG DELIVERY; PAMAM DENDRIMERS; TRANSEPITHELIAL TRANSPORT;

BIOCHEMISTRY; BODY FLUIDS; DENDRIMERS; DISEASES; DRUG DELIVERY; ESTERS; OPTIMIZATION; TOXICITY;

AMINO ACIDS;

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BETA ALANINE; GLYCINE; POLYAMIDOAMINE;

ARTICLE; CELL STRAIN CACO 2; CELL VIABILITY; COLORECTAL CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG STABILITY; DRUG TRANSPORT; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; IC 50; LIVER CANCER; METASTASIS; PRIORITY JOURNAL;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; CACO-2 CELLS; CAMPTOTHECIN; CELL LINE, TUMOR; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; COLORECTAL NEOPLASMS; DENDRIMERS; HUMANS;

EID: 79955051898     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2010.11.022     Document Type: Article

References (37)

1. R. Duncan The dawning era of polymer therapeutics Nat. Rev. Drug Discov. 2 5 2003 347 360 (Pubitemid 37361705)
2. M.J. Vicent, and R. Duncan Polymer conjugates: nanosized medicines for treating cancer Trends Biotechnol. 24 1 2006 39 47 (Pubitemid 43017749)
3. J. Kopecek, and P. Kopeckova HPMA copolymers: origins, early developments, present, and future Adv. Drug Deliv. Rev. 62 2 2010 122 149
4. G. Pasut, and F.M. Veronese PEG conjugates in clinical development or use as anticancer agents: an overview Adv. Drug Deliv. Rev. 61 13 2009 1177 1188
5. C.A. Lipinski Drug-like properties and the causes of poor solubility and poor permeability J. Pharmacol. Toxicol. Meth. 44 1 2000 235 249 (Pubitemid 32239479)
6. M. Findlay, G. von Minckwitz, and A. Wardley Effective oral chemotherapy for breast cancer: pillars of strength Ann. Oncol. 19 2 2008 212 222 (Pubitemid 351201700)
7. K. Le Lay, E. Myon, S. Hill, L. Riou-Franca, D. Scott, M. Sidhu, D. Dunlop, and R. Launois Comparative cost-minimisation of oral and intravenous chemotherapy for first-line treatment of non-small cell lung cancer in the UK NHS system Eur. J. Health Econ. 8 2 2007 145 151 (Pubitemid 46742894)
8. S. Pashko, and D.H. Johnson Potential cost savings of oral versus intravenous etoposide in the treatment of small cell lung cancer Pharmacoeconomics 1 4 1992 293 297
9. S. Chang, S.R. Long, L. Kutikova, L. Bowman, D. Finley, W.H. Crown, and C.L. Bennett Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000 J. Clin. Oncol. 22 17 2004 3524 3530 (Pubitemid 41109929)
10. O.M. Milhem, C. Myles, N.B. McKeown, D. Attwood, and A. D'Emanuele Polyamidoamine starburst dendrimers as solubility enhancers Int. J. Pharm. 197 1-2 2000 239 241 (Pubitemid 30125795)
11. D.A. Tomalia, L.A. Reyna, and S. Svenson Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging Biochem. Soc. Trans. 35 Pt 1 2007 61 67
12. R. Duncan, and L. Izzo Dendrimer biocompatibility and toxicity Adv. Drug Deliv. Rev. 57 15 2005 2215 2237 (Pubitemid 41759394)
13. C.C. Lee, J.A. MacKay, J.M. Fréchet, and F.C. Szoka Designing dendrimers for biological applications Nat. Biotechnol. 23 12 2005 1517 1526 (Pubitemid 41752929)
14. R. Wiwattanapatapee, B. Carreño-Gómez, N. Malik, and R. Duncan Anionic PAMAM dendrimers rapidly cross adult rat intestine in vitro: a potential oral delivery system? Pharm. Res. 17 8 2000 991 998
15. K.M. Kitchens, R.B. Kolhatkar, P.W. Swaan, N.D. Eddington, and H. Ghandehari Transport of poly (amido amine) dendrimers across Caco-2 cell monolayers: influence of size, charge and fluorescent labeling Pharm. Res. 23 12 2006 2818 2826 (Pubitemid 44885368)
16. A. D'Emanuele, R. Jevprasesphant, J. Penny, and D. Attwood The use of a dendrimer-propranolol prodrug to bypass efflux transporters and enhance oral bioavailability J. Control. Release 95 3 2004 447 453 (Pubitemid 38340495)
17. R.B. Kolhatkar, P.W. Swaan, and H. Ghandehari Potential oral delivery of 7-ethyl-10-hydroxy-camptothecin (SN-38) using poly (amido amine) dendrimers Pharm. Res. 25 7 2008 1723 1729
18. D. Sweet, R. Kolhatkar, A. Ray, P. Swaan, and H. Ghandehari Transepithelial transport of PEGylated anionic poly (amido amine) dendrimers: implications for oral drug delivery J. Control. Release 138 1 2009 78 85
19. M. El-Sayed, C.A. Rhodes, M. Ginski, and H. Ghandehari Transport mechanism(s) of poly (amido amine) dendrimers across Caco-2 cell monolayers Int. J. Pharm. 265 1-2 2003 151 157 (Pubitemid 37176956)
20. K.M. Kitchens, R.B. Kolhatkar, P.W. Swaan, and H. Ghandehari Endocytosis inhibitors prevent poly (amido amine) dendrimer internalization and permeability across Caco-2 cells Mol. Pharm. 5 2 2008 364 369 (Pubitemid 351579139)
21. D.S. Goldberg, H. Ghandehari, and P.W. Swaan Cellular entry of G3.5 poly (amido amine) dendrimers by clathrin- and dynamin-dependent endocytosis promotes tight junctional opening in intestinal epithelia Pharm. Res. 27 8 2010 1547 1557
22. R. Jevprasesphant, J. Penny, D. Attwood, and A. D'Emanuele Transport of dendrimer nanocarriers through epithelial cells via the transcellular route J. Control. Release 97 2004 259 267 (Pubitemid 38759483)
23. Y. Kawato, M. Aonuma, Y. Hirota, H. Kuga, and K. Sato Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11 Cancer Res. 51 16 1991 4187 4191
24. G. Xu, W. Zhang, M.K. Ma, and H.L. McLeod Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan Clin. Cancer Res. 8 8 2002 2605 2611 (Pubitemid 34856347)
25. M.L. Rothenberg Irinotecan (CPT-11): recent developments and future directions-colorectal cancer and beyond Oncologist 6 1 2001 66 80 (Pubitemid 32155817)
26. N. Vijayalakshmi, A. Ray, A. Malugin, and H. Ghandehari Carboxyl terminated PAMAM-SN38 conjugates: synthesis, characterization, and in vitro evaluation Bioconjug. Chem. 21 10 2010 1804 1810
27. H. Zhao, B. Rubio, P. Sapra, D. Wu, P. Reddy, P. Sai, A. Martinez, Y. Gao, Y. Lozanguiez, C. Longley, L.M. Greenberger, and I.D. Horak Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers Bioconjug. Chem. 19 4 2008 849 859 (Pubitemid 351614540)
28. E. Roger, F. Lagarce, and J.-P. Benoit The gastrointestinal stability of lipid nanocapsules Int. J. Pharm. 379 2 2009 260 265
29. M. Ahlmark, J. Vepsäläinen, H. Taipale, R. Niemi, and T. Järvinen Bisphosphonate prodrugs: synthesis and in vitro evaluation of novel clodronic acid dianhydrides as bioreversible prodrugs of clodronate J. Med. Chem. 42 8 1999 1473 1476 (Pubitemid 29200884)
30. F. Gabor, C. Fillafer, L. Neutsch, G. Ratzinger, and M. Wirth Improving oral delivery Handb. Exp. Pharmacol. 197 2010 345 398
31. R. Kimsey, and E. Harding A spectrophotometric assay optimizing conditions for pepsin activity Am. Biol. Teach. 60 3 1998 200 201
32. M. Mullally, D. OCallaghan, R. FitzGerald, W. Donnelly, and J. Dalton Proteolytic and peptidolytic activities in commercial pancreatic protease preparations and their relationship to some ehey protein hydrolysate characteristics J. Agric. Food Chem. 42 1994 2961 2973
33. C.E. Wheelock, T.F. Severson, and B.D. Hammock Synthesis of new carboxylesterase inhibitors and evaluation of potency and water solubility Chem. Res. Toxicol. 14 12 2001 1563 1572 (Pubitemid 34016619)
34. C.F. Stewart, W.C. Zamboni, W.R. Crom, and P.J. Houghton Disposition of irinotecan and SN-38 following oral and intravenous irinotecan dosing in mice Cancer Chemother. Pharmacol. 40 3 1997 259 265 (Pubitemid 27258664)
35. W. Yamamoto, J. Verweij, P. de Bruijn, M.J. de Jonge, H. Takano, M. Nishiyama, M. Kurihara, and A. Sparreboom Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells Anticancer Drugs 12 5 2001 419 432 (Pubitemid 32643086)
36. K.M. Kitchens, M.E. El-Sayed, and H. Ghandehari Transepithelial and endothelial transport of poly (amido amine) dendrimers Adv. Drug Deliv. Rev. 57 15 2005 2163 2176 (Pubitemid 41759391)
37. M.E. Fox, S. Guillaudeu, J.M. Frechet, K. Jerger, N. Macaraeg, and F.C. Szoka Synthesis and in vivo antitumor efficacy of PEGylated poly(l-lysine) dendrimer-camptothecin conjugates Mol. Pharm. 6 5 2009 1562 1572